GILD Q4 2025

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025

Earnings

Gilead Sciences capped Q4 2025 with a clean beat on both top and bottom lines, reporting non-GAAP diluted EPS of $1.86 against a consensus estimate of $1.85 while revenue climbed 4.7% year-over-year to $7.92 billion, topping the $7.69 billion analyst… Read more Gilead Sciences capped Q4 2025 with a clean beat on both top and bottom lines, reporting non-GAAP diluted EPS of $1.86 against a consensus estimate of $1.85 while revenue climbed 4.7% year-over-year to $7.92 billion, topping the $7.69 billion analysts had expected. The quarter's strength was anchored in Gilead's HIV and Liver Disease portfolios, with Biktarvy continuing to serve as the company's dominant growth engine and the newly launched Yeztugo, the world's first twice-yearly HIV prevention therapy, adding a fresh commercial catalyst to an already resilient franchise. Higher acquired IPR&D expenses, including $539 million tied to the Interius BioTherapeutics acquisition and Pregene collaboration, weighed on margins but did not derail the broader earnings picture. Separately, Gilead's announced acquisition of Arcellx for up to $7.8 billion signals an accelerating push into oncology that could reshape its long-term revenue mix. Looking ahead, management guided 2026 product sales of $29.60 to $30.00 billion and non-GAAP EPS of $8.45 to $8.85, projecting continued momentum from Yeztugo, Livdelzi, and potential new cancer therapy launches.